Atezolizumab

Atezolizumab (brand name Tecentriq) is a humanized monoclonal antibody immunotherapy designed to treat various advanced cancers—including NSCLC, SCLC, liver cancer, and melanoma—by blocking the PD-L1 protein to boost the immune system’s ability to attack cancer cells. It is approved as a single agent or with chemotherapy, targeting specific PD-L1 expressing tumors